NCT00309972View on ClinicalTrials.gov

Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

February 28, 2011

Study Completion Date

February 29, 2012

Conditions
Lung Cancer
Interventions
DRUG

Control arm (SEQ):

Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).

DRUG

Experimental arm (CON):

concurrent chemo-radiotherapy \[55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20\] followed by two cycles of cisplatinum/vinorelbine.

Trial Locations (1)

CH63 4JY

Clatterbridge Centre for Oncology, Merseyside

All Listed Sponsors
lead

University College, London

OTHER

NCT00309972 - Cisplatin, Vinorelbine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter